St. Jude Children's Research Hospital and Cesca Therapeutics Enter Into Collaboration Agreement Targeting Bone Marrow Transplantation

Cesca Therapeutics Inc.

, an autologous cell-based regenerative medicine company, today announced that it has entered into a collaboration agreement with St. Jude Children's Research Hospital, Memphis, Tennessee. Under the terms of the agreement, St. Jude Children's Research Hospital will evaluate a prototype for a new CellWerksTM device under Cesca's "Early Technology Access Program". The new device will specifically address the need for reduced red blood cell content in stem cell preparation for patients at risk of major blood-type mismatches. Commercial launch of the new device is expected in late 2016. Mitchel Sivilotti, Senior Vice President and Chief Biologist at Cesca Therapeutics stated, "This exciting collaboration with St. Jude Children's Research Hospital, one of the world's leading pediatric treatment and research facilities focused on children's catastrophic diseases, is a strategic next-step to Cesca's recent announcements addressing life-saving areas of need in hematology/oncology. We are in a unique position to develop and commercialize rapid cell isolation technology for multiple clinical applications and view major blood-type mismatch as one of the cornerstones of our growing CellWerks portfolio. This project, in addition to recent developments in our Haplo-identical Transplant program in India, represents a robust approach to addressing this growing, high value space."